Navigation Links
Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
Date:6/2/2009

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave(R) (naltrexone sustained release (SR)/bupropion SR) presentations taking place at the American Diabetes Association (ADA) 69th Scientific Sessions, June 5-9, 2009, and the 91st Annual Meeting of the Endocrine Society (ENDO), June 10-13, 2009.

ADA: Ernest N. Morial Convention Center, New Orleans, LA.

    Saturday, June 6:  Embargo Lifts June 6 at 9:00 a.m. CT
    Oral Presentation
    Abstract: 37-OR
    Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of
    Medicine, Philadelphia, PA
    Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss:
    A 56-week Phase 3 Study"
    Time: 9:00 a.m. CT
    Location: Room 255

    Monday, June 8:  Embargo Lifts June 6 at 10:00 a.m. CT
    Poster Presentation*
    Abstract: 1731-P
    Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of
    Medicine, Philadelphia, Pa.
    Title: "Naltrexone + Bupropion Combination Causes Weight Loss and Improves
    Quality of Life"
    Time: 12:00 - 2:00 p.m. CT
    Location: Hall E

    Poster Presentation*
    Abstract: 1730-P
    Presenter: Samuel Klein, M.D., Washington University School of Medicine,
    St. Louis, Mo.
    Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss
    Without Worsening Psychiatric Symptoms"
    Time: 12:00 - 2:00 p.m. CT
    Location: Hall E

    * Posters will also be presented Sunday, June 7 from 6:30 - 7:45 p.m. CT
    at a Poster Reception in Hall E

ENDO: Walter E. Washington Convention Center, Washington, D.C.

    Friday, June 12:  Embargo Lifts June 12 at 11:15 a.m. ET
    Oral Presentation
    Abstract: OR18-5
    Presenter: F. Xavier Pi-Sunyer, M.D., M.P.H., The New York Obesity
    Research Center, St. Luke's Roosevelt Hospital Center, New York, N.Y.
    Title: "Combination Therapy with Naltrexone + Bupropion Causes Significant
    Weight Loss and Improves Cardiometabolic Parameters in Obese Individuals:
    A Randomized Phase 3 Study Over 56 Weeks"
    Time: 11:15 a.m. ET
    Location: Room 152AB

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
6. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
7. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
8. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
9. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
10. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
11. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... ... antibody therapeutics from millions-diverse immune repertoires, announces launch of its new Surge(TM) ... Dave Johnson, PhD, CEO of GigaGen, will present on Surge at the conference. ...
(Date:6/19/2017)... ... June 19, 2017 , ... Tunnell Consulting has ... years. One of the biggest challenges faced by life sciences, biotech and pharmaceuticals companies ... team is Kati Abraham , who is well known in the industry and ...
(Date:6/16/2017)... ... June 16, 2017 , ... ... solutions, today announced that its Anzo Smart Data Lake® (Anzo SDL) solution ... category for the 2017 Software & Information Industry Association (SIIA) CODiE Awards. ...
(Date:6/15/2017)... ... June 15, 2017 , ... Cybrexa Therapeutics, ... B round of financing in the amount of $6 million. An investment vehicle ... in the round. , The Series B funding will enable Cybrexa to complete ...
Breaking Biology Technology:
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
Breaking Biology News(10 mins):